Flag of the European Union EU Clinical Trials Register Help

Clinical trials for SAFETY

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27,999 result(s) found for: SAFETY. Displaying page 1,075 of 1,400.
    «« First « Previous 1071  1072  1073  1074  1075  1076  1077  1078  1079  Next» Last»»
    EudraCT Number: 2005-003463-23 Sponsor Protocol Number: PETACC 8 Start Date*: 2006-04-04
    Sponsor Name:Fédération Francophone de Cancérologie Digestive (FFCD)
    Full Title: ADJUVANT TREATMENT OF FULLY RESECTED STAGE III COLON CANCER WITH FOLFOX-4 VERSUS FOLFOX-4 PLUS CETUXIMAB Tratamiento adyuvante con FOLFOX-4 versus FOLFOX-4 + cetuximab para el cáncer de colon en ...
    Medical condition: FULLY RESECTED STAGE III COLON CANCER CANCER DE COLON EN ESTADIO III EXTIRPADO COMPLETAMENTE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) DE (Completed) AT (Completed) BE (Completed) PT (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002302-32 Sponsor Protocol Number: C16017 Start Date*: 2013-11-12
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma
    Medical condition: Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10029478 Nodular lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003055-60 Sponsor Protocol Number: RIO-40400 Start Date*: 2014-10-10
    Sponsor Name:Medical University of Vienna
    Full Title: Evaluation of the pharmacodynamic effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction in a randomized, double blind, placebo controlled, ...
    Medical condition: Pulmonary hypertension and heart failure with preserved ejection fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006766-21 Sponsor Protocol Number: MINI-SPIOMET Start Date*: 2022-09-02
    Sponsor Name:Hospital de Girona Dr. Josep Trueta
    Full Title: Towards a treatment for accelerated maturation in girls testing spiomet in a randomised placebo controlled, multicentre study.
    Medical condition: Girls with advanced puberty and accelerated bone maturation. Polycystic Ovary Syndrome (PCOS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10014054 Early puberty LLT
    Population Age: Children, Under 18 Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002613-31 Sponsor Protocol Number: 009896QM Start Date*: 2015-04-27
    Sponsor Name:Queen Mary University of London
    Full Title: A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers.
    Medical condition: Triple-Negative Breast Cancer Non-squamous Small Cell Lung Cancer Squamous Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-003278-34 Sponsor Protocol Number: IRFMN-HIV-6986 Start Date*: 2015-12-02
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: A RANDOMIZED, CROSS-OVER, BIOEQUIVALENCE STUDY OF EFAVIRENZ TABLETS 600 mg OF MYLAN SpA AND SUSTIVA® (EFAVIRENZ) TABLETS 600 mg OF BRISTOL MYERS SQUIBB AT STEADY STATE IN PATIENTS WITH HIV-1
    Medical condition: Patients with HIV-1
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003286-21 Sponsor Protocol Number: SVUH-UCD-LEAD/CAR/01/2014 Start Date*: 2015-08-17
    Sponsor Name:University College Dublin
    Full Title: A multicentre, interventional, parallel group, randomised, open-label, exploratory study to assess the earlier introduction of Ivabradine in the Management of Systolic Dysfunction Heart Failure. Th...
    Medical condition: Heart Failure with reduced ejection fraction and borderline systolic blood pressure.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003328-22 Sponsor Protocol Number: 56022473MDS2002 Start Date*: 2017-02-13
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects with Low or Intermediate-1 Risk Myelodysplast...
    Medical condition: Transfusion-Dependent Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) who are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005370-62 Sponsor Protocol Number: ANAKIN-RA-DIABETES Start Date*: 2013-02-18
    Sponsor Name:OSPEDALE CIVILE SAN SALVATORE, ASL 04, L'AQUILA
    Full Title: “No-profit” clinical study for the improvement of clinical practice, to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabe...
    Medical condition: rheumatoid arthritis and type 2 diabetes mellitus as comorbidity.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10037740 RA LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003487-75 Sponsor Protocol Number: CARMEN Start Date*: 2011-10-03
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Phase II trial on safety and activity of intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt's lymphoma.
    Medical condition: Burkitt's lymphoma in HIV-positive patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006595 Burkitt's lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003320-51 Sponsor Protocol Number: 2013/24 Start Date*: 2015-04-29
    Sponsor Name:CENTRE ANTOINE LACASSAGNE
    Full Title: A phase 1/2 clinical trial to assess safety and efficacy of a new treatment for Hodgkin lymphoma's disease combining Adcetris¿ and Levact¿ in Old patients
    Medical condition: Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000460-34 Sponsor Protocol Number: ALCAT Start Date*: 2015-11-18
    Sponsor Name:Hospital of the University of Munich
    Full Title: Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT)
    Medical condition: Cerebellar ataxia is a form of ataxia originating in the cerebellum and is most often caused by neurodegenerative disorders of the cerebellum, either hereditary or sporadic. The leading clinical sy...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000589-31 Sponsor Protocol Number: NEMESIS Start Date*: 2018-02-02
    Sponsor Name:SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA
    Full Title: multi stage phase II trial of Nivolumab (an anti –PD-1) in patients with platinum resistant Mismatch Repair deficient germinal cells tumours
    Medical condition: patients with platinum resistant Mismatch Repair deficient germinal cells tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003542-17 Sponsor Protocol Number: FISM_IRON-MDS Start Date*: 2019-05-06
    Sponsor Name:FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE ETS
    Full Title: Early and low dose Deferasirox (3.5 mg/kg FCT) to suppress NTBI and LPI as early intervention to prevent tissue iron overload in lower risk MDS
    Medical condition: Adult patients with low risk MDS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028532 Myelodysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002340-32 Sponsor Protocol Number: APIDULCIS Start Date*: 2019-03-19
    Sponsor Name:FONDAZIONE ARIANNA ANTICOAGULAZIONE
    Full Title: APIDULCIS: Extended anticoagulation with low-dose apixaban after a standard course anticoagulation in patients with a first venous thromboembolism who have positive d-dimer
    Medical condition: a first episode of proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    21.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001868-19 Sponsor Protocol Number: 2015-001 Start Date*: 2015-10-15
    Sponsor Name:University medical center of Johannes Gutenberg University Mainz
    Full Title: A randomized, double-blind, placebo-controlled, mono-center study to evaluate the effects of mepolizumab on airway physiology in patients with eosinophilic asthma: the MEMORY study
    Medical condition: severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003862-10 Sponsor Protocol Number: Dara-Atra Start Date*: 2016-04-01
    Sponsor Name:VU University Medical Center
    Full Title: A phase 1 and phase 2 study of daratumumab in combination with all-trans retinoic acid in relapsed/refractory multiple myeloma
    Medical condition: relapsed/refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002171-19 Sponsor Protocol Number: HEVACC Start Date*: 2021-05-12
    Sponsor Name:Medizinische Universität Innsbruck, Institut für Virologie
    Full Title: Heterologous vaccination with a Vaxzervia (ChAdOx1-S) prime and a Comirnaty (BNT162b2) boost
    Medical condition: Immunization for SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10021433 Immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005745-16 Sponsor Protocol Number: 77119 Start Date*: 2021-03-22
    Sponsor Name:Steno Diabetes Center Copenhagen
    Full Title: Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People with Type 1 Diabetes: A Randomized, Open-Label, Two-Period Crossover Outpatient Study
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-001368-43 Sponsor Protocol Number: MVT-601-035 Start Date*: 2019-01-21
    Sponsor Name:Myovant Sciences GmbH
    Full Title: An International Phase 3 Double-Blind, Placebo-controlled, Randomized Withdrawal Study of Relugolix Co-administered with Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding A...
    Medical condition: heavy menstrual bleeding associated with uterine fibroids
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10027331 Menstrual flow altered LLT
    21.1 100000004864 10046783 Uterine fibroid LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) HU (Completed) BE (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1071  1072  1073  1074  1075  1076  1077  1078  1079  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 10:05:46 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA